Research Article: Prognostic Significance of Pretreatment Plasma D-dimer Levels in EGFR-Positive Advanced Non-Small Cell Lung Cancer Patients Receiving Osimertinib: A Multicentre Retrospective Study
Introduction:
Activating the epidermal growth factor receptor is a common oncogenic driver in NSCLC. Approximately –% of all EGFR-activating mutations are accounted for by deletions in exon and point mutations in exon , specifically the LR mutation. Currently, EGFR-tyrosine kinase inhibitors (TKIs) are regarded as the standard first-line therapy for advanced non-small cell lung cancer (NSCLC) with EGFR mutations. The TKIs, which consist of both first- and second-generation agents, have demonstrated a substantial increase in…
Read more